Quantcast

Latest Neuronetics Stories

2014-05-06 16:32:06

Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK, May 6, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice...

2014-05-06 14:42:47

Pilot study reveals a majority of medication-free patients treated with NeuroStar TMS experienced remission after 6 weeks with durable effects through 3 months Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy® for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced...

2014-05-05 16:26:47

Pilot Study Reveals a Majority of Medication-Free Patients Treated with NeuroStar TMS Experienced Remission After Six Weeks with Durable Effects Through Three Months NEW YORK, May 5, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(®) for Major Depressive Disorder (MDD)....

2014-01-27 08:28:26

510(k) filing follows recent FDA clearance of CerenaTMS(TM) SUNNYVALE, Calif. and BALTIMORE, Jan. 27, 2014 /PRNewswire/ -- eNeura Inc., a privately held medical technology company, announced today that it filed a 510(k) with the U.S. Food and Drug Administration (FDA) for the SpringTMS(®) transcranial magnetic stimulation (TMS) device. SpringTMS is a second-generation medical device based on eNeura's ground-breaking CerenaTMS(TM), which recently received FDA clearance for the...

2013-05-22 10:36:51

Largest clinical study evaluating durability of Transcranial Magnetic Stimulation shows depression patients maintained remission through 52 weeks with the NeuroStar New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System® induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related